Identify genetic health risks early

You know your patients and their families better than most doctors. But family history alone isn’t enough to determine a woman's risk of cancer and cardiovascular disease. Comprehensive risk assessment and genetic testing for all women helps you identify those who need additional health care.1

Provider Ob/Gyn – genetic testing for woman’s health
Middle aged dark haired yellow shirt female back profile in circular shape

Genetic cancer screening can help you uncover a women’s hereditary health risk before you find a lump

1 in 4 women in the general population meet criteria for hereditary cancer genetic testing.1

  • Nearly half of patients with a BRCA1 or BRCA2 genetic variant do not have a suggestive family history—but need additional care2
  • Cancer risk doesn’t end with a negative genetic test report. A Tyrer-Cuzick score can be included with results to help you personalize a screening plan.*
Black female with partial smile

You can give women a better chance at catching cancer early or preventing it altogether with genetic testing

Early identification through genetic testing leads to improved outcomes for women. For patients with BRCA1 or BRCA2 variants, knowing their genetic status before a breast cancer diagnosis leads to improved survival rates.3

For those patients who test negative for pathogenic variants, Invitae can provide a Tyrer-Cuzick score, so you can get a more complete picture.

5-year survival rates improve when patients know their BRCA status

The 5-year survival rate in patients who knew their BRCA1/BRCA2 status before diagnosis is 94% compared with 78% in patients who only found out their status after diagnosis (P<0.03).3

78

%

Status unknown at diagnosis

94

%

Status known before diagnosis

See tests

Test today for their tomorrow

ACOG=American College of Obstetrics and Gynecology
AHA=American Heart Association


*Not available in the EU and UK

References

1. Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7(2):230–237. doi:10.1001/jamaoncol.2020.6252.
2. ACOG Committee Opinion No. 793: Hereditary cancer syndromes and risk assessment. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2019;134(6):e143-e149.
3. Hadar T, Mor P, Amit G, et al. Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer. Letter. JAMA Oncol. 2020;6(9):1460-1463. doi:10.1001/jamaoncol.2020.2059.
4. Brown HL, Warner JJ, Gianos E, et al. On behalf of the American Heart Association and the American College of Obstetricians and Gynecologists. Promoting risk identification and reduction of cardiovascular disease in women through collaboration with obstetricians and gynecologists: a presidential advisory from the American Heart Association and the American College of Obstetricians and Gynecologists. Circulation. 2018;137:e843–e852. doi:10.1161/CIR.0000000000000582.
5. Women and heart disease. Centers for Disease Control and Prevention website. Updated January 31, 2020. Accessed March 24, 2021. https://www.cdc.gov/heartdisease/women.htm.
6. Newson L. Menopause and cardiovascular disease. Post Reprod Health. 2018;24(1):44-49. doi:10.1177/2053369117749675.
7. Shah ASV, Griffiths M, Lee KK, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873. doi:10.1136/bmj.g7873.
8. Alabas OA, Gale CP, et al. Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: National cohort study using the SWEDEHEART Registry. J. Am. Heart Assoc. 2017;6(12):e007123. doi: 10.1161/JAHA.117.007123.
9. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254. doi:10.1016/j.jacc.2015.01.019.
10. Musunuru K, Hershberger RE, Day SM, et al. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2020;13(4):e000067. doi:10.1161/HCG.0000000000000067.
11. U.S. public opinion about personalized medicine. Personalized Medicine Coalition. Accessed April 2020.